Cardiac preservation using <i>ex vivo</i> organ perfusion: new therapies for the treatment of heart failure by harnessing the power of growth factors using BMP mimetics like THR-184.

Front Cardiovasc Med · 2025 · PMC11960666 · PMID 40171539

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A large clinical trial of transendocardial mesenchymal precursor cells in patients with heart failure did not reach statistical significance for its primary and secondary endpoints ( 87 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Cardiac preservation using &lt;i&gt;ex vivo&lt;/i&gt; organ perfusion: new therapies for the treatment of heart failure by harnessing the power of growth factors using BMP mimetics like THR-184.

The sentences

Cardiac preservation using <i>ex vivo</i> organ perfusion: new therapies for the treatment of heart failure by harnessing the power of growth factors using BMP mimetics like THR-184.